

# **OPERATION WARP SPEED** VACCINE DISTRIBUTION PROCESS

# IN SUPPORTING THE DISTRIBUTION & ADMINISTRATION OF COVID-19 VACCINES, OWS HAS FOUR KEY GOALS, TENETS, AND ARCHITECTURE



Ensure safety and effectiveness of COVID-19 vaccines



Reduce morbidity and mortality of COVID-19 disease through effective and efficient distribution of COVID-19 vaccines



Support rapid vaccine distribution based on CDC guidance for states immunizations services



Assist with the return to pre-pandemic quality of life

# DISTRIBUTION AND ADMINISTRATION OF A COVID-19 VACCINE FOUR KEY TENETS

times in the process o	<b>TY</b> secondary item kits are at all of distribution and ensuring the zed groups as determined by		<b>COVERAGE</b> Deliver vaccines beyond the normal brick and mortar facilities, including potential mobile or on-site delivery of vaccine to long-term healthcare facilities and other hard to reach populations
<b>UPTAKE</b> How many vaccines v per day to match sup	vere administered per location ply with demand		<b>TRACEABILITY</b> Confirm which of the approved vaccines were administered: • Regardless of location (private/public) • Reminder to return for second dose • Administer the correct second dose
TRIALS	<section-header>FDA Based on data from clinical trials, vaccine candidate is submitted for mergency Use Authorization (EUA) or Biologics License Application (BLA) • Reviews EUA/BLA application • Approves EUA/BLA application • Oversees ongoing reporting • Pharmacovigilance</section-header>	AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	<image/> <section-header><section-header><section-header><section-header><section-header><section-header><text><text></text></text></section-header></section-header></section-header></section-header></section-header></section-header>
	$\bigcirc$		



#### **ADMINISTRATION SITES**

Vaccines, upon EUA/BLA, are ready to ship to:

- Pharmacies
- Nursing homes
- Public Clinics
- Hospitals
- Doctor's offices and Mobile Clinics
- Military Treatment Facilities

## DISTRIBUTION FACILITIES

Vaccines & associated ancillary kits (syringes, needles, and alcohol swabs) will be shipped concurrently to distribution depots and facilities

### DISTRIBUTOR

- Maximize use of existing pharmaceutical distribution infrastructure
- Central Distributor established for kitting & distribution operations
- IT infrastructure supports ordering, distribution, administration, and tracking end-to-end

PHARMACOVIGILANCE (FDA & CDC)

24 month post trial monitoring for adverse effects/additional safety feature